Your browser is no longer supported. Please, upgrade your browser.
Settings
AIMT Aimmune Therapeutics, Inc. daily Stock Chart
AIMT [NASD]
Aimmune Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.00 Insider Own0.10% Shs Outstand63.76M Perf Week-7.84%
Market Cap1.51B Forward P/E- EPS next Y-3.44 Insider Trans-36.31% Shs Float46.56M Perf Month4.95%
Income-168.00M PEG- EPS next Q-0.92 Inst Own80.50% Short Float14.26% Perf Quarter-10.01%
Sales- P/S- EPS this Y-9.60% Inst Trans0.16% Short Ratio9.15 Perf Half Y-18.48%
Book/sh4.24 P/B5.60 EPS next Y5.50% ROA-65.90% Target Price55.00 Perf Year-39.82%
Cash/sh4.00 P/C5.93 EPS next 5Y34.60% ROE-74.80% 52W Range21.38 - 42.00 Perf YTD-0.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.50% Beta-0.06
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low10.99% ATR1.58
Employees203 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)44.58 Volatility5.68% 6.46%
OptionableYes Debt/Eq0.00 EPS Q/Q-40.80% Profit Margin- Rel Volume3.01 Prev Close24.30
ShortableYes LT Debt/Eq0.00 EarningsFeb 07 BMO Payout- Avg Volume725.91K Price23.73
Recom1.90 SMA20-1.04% SMA50-6.74% SMA200-15.68% Volume2,188,449 Change-2.35%
Dec-13-18Initiated Goldman Neutral $32
May-18-18Resumed Piper Jaffray Overweight
Feb-07-18Initiated RBC Capital Mkts Outperform $55
Dec-21-17Initiated Robert W. Baird Outperform $64
Nov-20-17Initiated ROTH Capital Buy
Sep-26-16Initiated JMP Securities Mkt Outperform
Mar-01-16Initiated Wedbush Outperform $42
Nov-17-15Reiterated Piper Jaffray Overweight $35 → $38
Aug-31-15Initiated Piper Jaffray Overweight $35
Aug-31-15Initiated Credit Suisse Outperform $44
Aug-31-15Initiated BofA/Merrill Buy $36
Jan-15-19 07:55AM  Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics ACCESSWIRE
07:22AM  Jim Cramer Shares His Thoughts On Alibaba, Dynavax, Starbucks And More Benzinga
Jan-14-19 06:50PM  Cramer's lightning round: The way to play Goldman's downgrade of Starbucks CNBC -5.19%
Jan-08-19 11:30AM  This Under-the-Radar Biotech Stock Is My Top Pick for 2019 TheStreet.com
Jan-04-19 08:45AM  Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement Business Wire
Jan-03-19 07:35AM  Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Jan-02-19 08:00AM  Aimmune Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th Business Wire
Dec-21-18 04:01PM  Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 417 Business Wire -9.25%
Dec-20-18 04:32PM  Why Tilray, Fortuna Silver Mines, and Aimmune Therapeutics Jumped Today Motley Fool +15.48%
01:05PM  These 4 Biotech Stocks are Picking Up Speed ACCESSWIRE
11:19AM  Delay for Peanut Allergy Drug Sinks Biotech Stock Bloomberg
10:00AM  Sell-Side Slashes DBV Tech Price Targets After Withdrawal Of BLA For Peanut Allergy Immunotherapy Benzinga
08:00AM  Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods Business Wire
07:00AM  Today's Research Reports on Trending Tickers: Aimmune Therapeutics and FibroGen ACCESSWIRE
02:20AM  [$$] DBV's US-Listed Shares Crash The Wall Street Journal
Dec-19-18 08:00AM  Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 13-Year-Old Children Business Wire
Dec-06-18 08:00AM  Aimmune Therapeutics to Host Investor Symposium on the Future of Treating Peanut Allergy with Leading Expert Allergists on Wednesday, December 12th Business Wire +6.07%
Nov-30-18 08:25AM  The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings Benzinga
Nov-28-18 04:05PM  Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science Business Wire
07:20AM  Market Trends Toward New Normal in Genomic Health, Beacon Roofing Supply, Cronos Group, Aimmune Therapeutics, OGE Energy, and Spartan Motors Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-26-18 10:04AM  Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics American City Business Journals
Nov-19-18 11:56PM  [$$] Peanut allergy treatment raises concerns over the potential cost Financial Times -11.24%
08:21PM  Here's Why Aimmune Therapeutics Closed Down 11.2% After Publishing Its "Landmark" Clinical Trial Motley Fool
01:47PM  Peanut Allergy Remedy Offers Both Hope and Risk Bloomberg
12:33PM  Biotech Slides As Investors Digest Results Of Peanut-Allergy Test Investor's Business Daily
Nov-18-18 10:47PM  [$$] Experimental Drug Shows Promise Protecting Against Peanut Allergies The Wall Street Journal
04:45PM  Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine Business Wire
Nov-14-18 08:48AM  Are Options Traders Betting on a Big Move in Aimmune Therapeutics (AIMT) Stock? Zacks
Nov-12-18 09:43AM  Nestle raises stake in food allergy drug developer Aimmune Reuters -7.73%
08:00AM  Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science Business Wire
Nov-08-18 04:37PM  Aimmune Therapeutics: 3Q Earnings Snapshot Associated Press -12.19%
04:01PM  Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights Business Wire
08:00AM  Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting Business Wire
Nov-02-18 08:00AM  Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors Business Wire
Nov-01-18 08:00AM  Aimmune Therapeutics to Participate in Upcoming Investor Conferences Business Wire +16.29%
Oct-17-18 08:55AM  New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-15-18 08:00AM  Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients Business Wire
Sep-26-18 08:00AM  Aimmune Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 3 Business Wire
Aug-29-18 08:00AM  Aimmune Therapeutics to Present at Three Investor Conferences in September Business Wire
Aug-08-18 04:59PM  Aimmune Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  Aimmune Therapeutics Announces Second Quarter 2018 Financial Results Business Wire
Aug-07-18 08:00AM  Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th Business Wire
Jun-28-18 02:30PM  With food allergies on the rise, biotech Aimmune is focusing on raising patients' tolerance CNBC
01:50PM  Partnering with Nestle to tackle food allergies: Former A... CNBC Videos
Jun-21-18 12:45PM  Aimmune Therapeutics: An Interesting Business and Charts to Watch TheStreet.com -8.71%
Jun-20-18 07:00PM  Cramer Remix: The battle between these stocks proves why tech triumphs CNBC
Jun-19-18 07:05AM  Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-15-18 07:40AM  New Research Coverage Highlights Avery Dennison, Raymond James Financial, Genuine Parts, Kimco Realty, Bristow Group, and Aimmune Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jun-11-18 04:01PM  Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO Business Wire
Jun-01-18 07:40AM  Wired News - Aimmune Therapeutics Presents Data from New Pan-European Study on Psychosocial Burden Associated with Peanut Allergy at EAACI Congress 2018 ACCESSWIRE
May-30-18 06:00AM  Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy Business Wire
May-29-18 07:30AM  Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018 Business Wire
May-28-18 11:15AM  Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress Business Wire
May-15-18 08:00AM  Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 Business Wire
May-10-18 07:15AM  Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks ACCESSWIRE
May-09-18 09:02AM  Stocks Insiders Just Bought This May Simply Wall St. -6.68%
08:00AM  Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June Business Wire
May-08-18 05:08PM  Aimmune Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Aimmune Therapeutics Announces First Quarter 2018 Financial Results Business Wire
Apr-19-18 08:15AM  Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J. Gallagher, Aimmune Therapeutics, Roku, and Premier Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Apr-04-18 09:02AM  April Stocks Insiders Just Bought Simply Wall St.
Apr-02-18 06:52PM  Is This Why AnaptysBio Inc. Fell on Monday? Motley Fool -6.85%
Mar-27-18 08:36AM  Protecting children from severe peanut allergies Fox Business Videos
Mar-26-18 05:34PM  After-hours buzz: RHT, ANAB & more CNBC
Mar-12-18 08:09AM  Aimmune Therapeutics reports 4Q loss Associated Press
08:00AM  Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Business Wire
Mar-07-18 08:00AM  Aimmune Therapeutics to Participate in Four Investor Conferences in March Business Wire
Mar-05-18 10:08AM  Company News For Mar 5, 2018 Zacks +5.58%
Mar-04-18 02:00PM  Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO Business Wire
Mar-02-18 04:01PM  Aimmune Therapeutics Announces Exercise in Full of Underwriters Option to Purchase Additional Shares of Common Stock Business Wire
12:58PM  Peanut Allergy-Focused Biotech May Strike Magic in Orlando Bloomberg
Feb-27-18 03:38PM  Insiders Are Frantically Buying Up These Cheap Stocks Insider Monkey +5.18%
07:00AM  Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando Business Wire
Feb-26-18 04:01PM  Aimmune Therapeutics Announces Closing of Public Offering of Common Stock Business Wire -7.98%
Feb-22-18 07:40AM  Wired News Aimmune Therapeutics Peanut Allergy Drug AR101 Met Primary Endpoint in Pivotal Phase-3 Clinical Trial ACCESSWIRE
Feb-21-18 07:28PM  Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock Business Wire -7.87%
12:53PM  Aimmune Therapeutics Is Moving on Allergy Data GuruFocus.com
12:00AM  [$$] A new peanut allergy drug could force a change of behaviour Financial Times
Feb-20-18 04:16PM  Aimmune Therapeutics Announces Proposed Public Offering of Common Stock Business Wire -6.02%
09:01AM  Aimmune shares surge 10% on positive late-stage trial results for peanut allergy drug MarketWatch
07:49AM  [$$] Aimmunes peanut allergy drug succeeds in late stage clinical trial Financial Times
07:24AM  Aimmune's peanut allergy drug meets main goal of key study Reuters
07:06AM  Aimmune's peanut allergy drug meets main goal of key study Reuters
07:00AM  Aimmune Therapeutics Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy Business Wire
01:23AM  [$$] Peanut allergy drug nears approval after clinical trial success Financial Times
Feb-14-18 01:18PM  Why DBV Technologies Jumped Higher Today Motley Fool
08:00AM  Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D. Business Wire
Feb-12-18 08:15AM  Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress Business Wire
Feb-08-18 08:15AM  Report: Exploring Fundamental Drivers Behind Stericycle, Hemisphere Media Group, Expedia, Olin, Aimmune Therapeutics, and Waste Management New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-13-18 10:00AM  How Trading Notes Can Increase Your Profits TheStreet.com
Jan-10-18 08:00AM  Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy Business Wire
Jan-08-18 08:00AM  Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy Business Wire
Jan-03-18 08:00AM  Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-13-17 11:18AM  Moore Loss Won't Stop Tax Bill; Bitcoin Plays Are Bubbling TheStreet.com +5.21%
Dec-07-17 08:00AM  Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14 Business Wire
Nov-30-17 03:42PM  Aimmune Therapeutics, Inc. Fundamental Analysis : November 30, 2017 Capital Cube +6.32%
Nov-20-17 08:00AM  Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1 Business Wire
07:35AM  Report: Developing Opportunities within UGI, Party City Holdco, Old Dominion Freight Line, Olin, Aimmune Therapeutics, and Waste Management Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-06-17 08:37AM  Aimmune Therapeutics reports 3Q loss Associated Press
08:30AM  Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018 Business Wire
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barrowcliffe Susan E.General Manager, EuropeNov 19Option Exercise3.0240,000120,88049,375Nov 21 04:05 PM
Dallas Jayson Donald AlexanderPresident and CEONov 19Buy27.563,650100,58763,650Nov 19 08:12 PM
Barrowcliffe Susan E.General Manager, EuropeNov 19Sale30.0440,0001,201,6009,375Nov 21 04:05 PM
BJERKHOLT ERICChief Financial OfficerJun 13Buy30.411,60048,66319,485Jun 14 04:08 PM
DILLY STEPHEN GEORGEPresident and CEOJun 11Option Exercise3.0229,45789,022344,765Jun 13 04:06 PM
DILLY STEPHEN GEORGEPresident and CEOJun 11Sale30.8329,457908,301315,308Jun 13 04:06 PM
DILLY STEPHEN GEORGEPresident and CEOJun 08Option Exercise3.0242,106127,249357,414Jun 08 05:50 PM
DILLY STEPHEN GEORGEPresident and CEOJun 08Sale30.7042,1061,292,511315,308Jun 08 05:50 PM
DILLY STEPHEN GEORGEPresident and CEOJun 07Option Exercise3.0232,59898,514347,906Jun 08 05:50 PM
DILLY STEPHEN GEORGEPresident and CEOJun 07Sale30.9632,5981,009,111315,308Jun 08 05:50 PM
DILLY STEPHEN GEORGEPresident and CEOJun 06Option Exercise3.0230,46592,068345,773Jun 08 05:50 PM
DILLY STEPHEN GEORGEPresident and CEOJun 06Sale31.2030,465950,371315,308Jun 08 05:50 PM
DILLY STEPHEN GEORGESee RemarksJun 05Option Exercise3.0238,825117,333354,133Jun 05 07:20 PM
DILLY STEPHEN GEORGESee RemarksJun 05Sale31.8338,8251,235,835315,308Jun 05 07:20 PM
DILLY STEPHEN GEORGESee RemarksJun 04Option Exercise3.0265,352197,500380,660Jun 05 07:20 PM
DILLY STEPHEN GEORGESee RemarksJun 04Sale31.8865,3522,083,356315,308Jun 05 07:20 PM
DILLY STEPHEN GEORGESee RemarksJun 01Option Exercise3.0261,197184,943376,505Jun 05 07:20 PM
DILLY STEPHEN GEORGESee RemarksJun 01Sale32.6261,1971,995,993315,308Jun 05 07:20 PM
Sheehy Douglas T.See RemarksMay 22Option Exercise12.953,29642,68334,727May 24 05:09 PM
Sheehy Douglas T.See RemarksMay 22Sale33.003,296108,76833,079May 24 05:09 PM
Sheehy Douglas T.See RemarksMar 05Option Exercise16.513,52358,14834,375Mar 06 08:40 PM
Sheehy Douglas T.See RemarksMar 05Sale36.523,523128,66732,500Mar 06 08:40 PM
Rozenman Mary M.See RemarksMar 01Option Exercise3.021,8075,4611,936Mar 05 04:05 PM
Rozenman Mary M.See RemarksMar 01Sale33.101,80759,812129Mar 05 04:05 PM
BJERKHOLT ERICChief Financial OfficerFeb 26Buy32.003,125100,0008,125Feb 26 04:05 PM
FALBERG KATHRYN EDirectorFeb 26Buy32.0030,000960,000124,894Feb 26 04:05 PM
Iwicki Mark TDirectorFeb 26Buy32.009,375300,00029,375Feb 26 04:05 PM
Tammenoms Bakker Juliet10% OwnerFeb 22Buy32.009,375300,00016,651Feb 26 04:25 PM
ENRIGHT PATRICK GDirectorFeb 22Buy32.0015,593498,97622,869Feb 26 04:22 PM
Sheehy Douglas T.See RemarksFeb 05Option Exercise12.951,64821,3421,648Feb 07 04:06 PM
Sheehy Douglas T.See RemarksFeb 05Sale35.871,64859,1140Feb 07 04:06 PM
Rozenman Mary M.See RemarksFeb 01Option Exercise3.026,59219,9216,721Feb 05 04:05 PM
Rozenman Mary M.See RemarksFeb 01Sale35.366,592233,088129Feb 05 04:05 PM
Sheehy Douglas T.See RemarksJan 24Option Exercise19.631,87536,8061,875Jan 26 05:32 PM
Sheehy Douglas T.See RemarksJan 24Sale38.151,87571,5310Jan 26 05:32 PM